SPRINGWORKS THERAPEUTICS INC (SWTX) Stock Price & Overview
NASDAQ:SWTX • US85205L1070
Current stock price
The current stock price of SWTX is 46.99 USD. Today SWTX is up by 0.02%. In the past month the price increased by 0.6%. In the past year, price increased by 27.79%.
SWTX Key Statistics
- Market Cap
- 3.539B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.41
- Dividend Yield
- N/A
SWTX Stock Performance
SWTX Stock Chart
SWTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SWTX. When comparing the yearly performance of all stocks, SWTX is one of the better performing stocks in the market, outperforming 81.49% of all stocks.
SWTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SWTX. SWTX has a great financial health rating, but its profitability evaluates not so good.
SWTX Earnings
On May 9, 2025 SWTX reported an EPS of -1.11 and a revenue of 49.09M. The company missed EPS expectations (-35.47% surprise) and missed revenue expectations (-27.36% surprise).
SWTX Forecast & Estimates
11 analysts have analysed SWTX and the average price target is 53.33 USD. This implies a price increase of 13.5% is expected in the next year compared to the current price of 46.99.
For the next year, analysts expect an EPS growth of 19.4% and a revenue growth 71.54% for SWTX
SWTX Groups
Sector & Classification
SWTX Financial Highlights
Over the last trailing twelve months SWTX reported a non-GAAP Earnings per Share(EPS) of -3.41. The EPS increased by 33.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.25% | ||
| ROE | -60.84% | ||
| Debt/Equity | 0 |
SWTX Ownership
SWTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.01 | 375.559B | ||
| AMGN | AMGEN INC | 15.38 | 191.693B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 176.393B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.5 | 113.496B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.02 | 81.177B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.17 | 42.608B | ||
| INSM | INSMED INC | N/A | 34.4B | ||
| NTRA | NATERA INC | N/A | 28.771B | ||
| BIIB | BIOGEN INC | 10.76 | 25.993B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.14 | 25.192B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| INCY | INCYTE CORP | 12.54 | 19.296B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.068B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SWTX
Company Profile
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. The company is headquartered in Stamford, Connecticut and currently employs 368 full-time employees. The company went IPO on 2019-09-13. The firm developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). The company is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Company Info
IPO: 2019-09-13
SPRINGWORKS THERAPEUTICS INC
100 Washington Blvd
Stamford CONNECTICUT 06902 US
CEO: Saqib Islam
Employees: 368
Phone: 12038839490
SPRINGWORKS THERAPEUTICS INC / SWTX FAQ
Can you describe the business of SPRINGWORKS THERAPEUTICS INC?
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. The company is headquartered in Stamford, Connecticut and currently employs 368 full-time employees. The company went IPO on 2019-09-13. The firm developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). The company is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
What is the stock price of SPRINGWORKS THERAPEUTICS INC today?
The current stock price of SWTX is 46.99 USD. The price increased by 0.02% in the last trading session.
Does SWTX stock pay dividends?
SWTX does not pay a dividend.
How is the ChartMill rating for SPRINGWORKS THERAPEUTICS INC?
SWTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of SWTX stock?
SPRINGWORKS THERAPEUTICS INC (SWTX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for SPRINGWORKS THERAPEUTICS INC?
SPRINGWORKS THERAPEUTICS INC (SWTX) has a market capitalization of 3.54B USD. This makes SWTX a Mid Cap stock.